More Benefit Observed With Avapritinib Than Other TKIs in Mutated GIST
May 21st 2021A retrospective analysis showed there were more durable survival outcomes with avapritinib versus other tyrosine kinase inhibitors in adult patients with gastrointestinal stromal tumors and a platelet-derived growth factor receptor A D842V mutation
Experts in Ovarian Cancer Discuss Targeted Agent Combinations and Disparities in Care
May 20th 2021The ovarian cancer treatment landscape, including the use of cytotoxic and targeted therapies, is continuously evolving for patients. Recent trials have evaluated PARP inhibitors, antiangiogenic agents, and other targeted therapies, and investigators are looking at strategies to individualize care for patients with ovarian cancer.
Prior Comorbidities Predict Risk of Treatment-Emergent Atrial Fibrillation in CLL
May 3rd 2021Roughly 4% of patients with chronic lymphocytic leukemia treated with ibrutinib may experience atrial fibrillation, but their comorbidities, rather than their CLL-related factors, predict risk of treatment-emergent AF.
Immune System Plays Important Role in CAR T Cell Responses in Glioblastoma Models
April 16th 2021Chimeric antigen receptor T-cell therapy mediates antigen-dependent and -independent antitumor effects, and CAR T-cell activation of host antitumor immunity is critical for productive solid tumor CAR T immunotherapy.
Texas Colon & Rectal Specialists Join Texas Oncology and The US Oncology Network
April 2nd 2021Surgical oncology expertise has been expanded to local communities in North Texas after physicians from Texas Colon & Rectal Specialists, a large colorectal cancer practice in North Texas, have joined Texas Oncology, increasing The US Oncology Network’s reach.
Positive Efficacy Seen With Derazantinib in FGFR2 Mutated or Amplified Bile Duct Cancer
March 26th 2021In a preplanned interim analysis of a phase 2 trial, derazantinib demonstrated antitumor efficacy and met the prespecified threshold for the trial to proceed to the next stage as planned for patients with inoperable or advanced intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions, mutations, or amplifications.
PFS Benefit Sustained at 5-Year Follow-Up in SOLO-1 Trial of Maintenance Olaparib in Ovarian Cancer
March 21st 2021After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.
Niraparib Shows Efficacy in Hard-to-Treat Patients With Newly Diagnosed Ovarian Cancer
March 19th 2021Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Bintrafusp Alfa Shows Efficacy but Does Not Meet Predetermined Threshold in BTC Trial
March 18th 2021Bintrafusp alfa monotherapy demonstrated efficacy, durability, and a manageable safety profile in patients with locally advanced or metastatic biliary tract cancer who have progressed or are intolerant to first-line platinum-based chemotherapy in a phase 2 study, but failed to meet the pre-determined threshold for a regulatory filing.
Kentucky Programs Boost CRC Screening Access for Uninsured, Underinsured
March 15th 2021Undergoing colorectal screening can be a challenge for people who don’t have insurance or are underinsured, so the Colon Cancer Prevention Project was created in Kentucky to help establish programs to improve access to screening, including the Kentucky Colon Cancer Screening and Prevention Program.
Pre-Emptive Treatment May Be Superior to Reactive Treatment of Hand–Foot Reactions in mCRC
February 25th 2021A preplanned analysis of the Regorafenib Dose Optimization Study in patients with metastatic colorectal cancer showed using pre-emptive clobetasol to treat hand–foot skin reactions was more effective than treating this adverse event reactively.
TIVO-3 Trial End Point Q-TWiST Increased With Tivozanib in RCC
February 12th 2021The VEGF tyrosine kinase inhibitor tivozanib hydrochloride demonstrated a significantly increased quality-adjusted time without symptoms of disease and toxicity as third- or fourth-line therapy in patients with metastatic renal cell carcinoma compared with sorafenib in the phase 3 TIVO-3 trial.
KTE-X19 Continues to Show Durable Efficacy in Relapsed/Refractory MCL
February 12th 2021After a minimum of 1 year of follow-up, patients with relapsed/refractory mantle cell lymphoma demonstrated substantial and durable clinical benefit and a manageable safety profile when receiving KTE-X19 chimeric antigen receptor T cell therapy.
Targeted Therapies Expand Reach on World Cholangiocarcinoma Day
February 12th 2021Over the last 10 years, the treatment landscape for biliary tract cancers, specifically intrahepatic cholangiocarcinoma, has evolved and now offers physicians more front- and second-line choices for their patients. For targeted agents in this setting, promising new data have come out for patients with actionable alterations.
Larotrectinib Shows Activity in Lung Cancer Harboring NTRK Gene Fusions
February 2nd 2021Larotrectinib was observed to be highly active and have a favorable safety profile in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.
Chemotherapy Improves PFS Over Targeted Therapy Combination in HR+, HER- Breast Cancer Subset
January 18th 2021Patients with hormone receptor-positive and HER2-negative, aromatase inhibitor resistant metastatic breast cancer experienced improvement in progression-free survival on treatment with chemotherapy over palbociclib in combination with and endocrine therapy.
COVID-19 and Stay-at-Home Orders Propel the Use of Telemedicine
December 27th 2020Response from oncologists and other clinicians who participated in a series of online educational seminars and Twitter polls showed that the conversion of follow-up visits to telemedicine for patients with lung cancer continues to expand, mainly due to effects of the COVID-19 pandemic.
New Medicare Model Could Negatively Impact Cancer Care, According to ACCC
December 19th 2020The Association of Community Cancer Centers urged the Centers for Medicare and Medicaid Services to withdraw from The Most Favored Nation Model Interim Final Rule with Comment Period due to fears of the disproportionate impact the model could have on cancer care.
Atezolizumab More Likely to Benefit Urothelial Cancer With Detectable ctDNA
December 12th 2020Adjuvant atezolizumab in patients with high-risk muscle-invasive urothelial cancer with detectable circulating tumor DNA demonstrated more benefit compared with those with MIUC and undetectable ctDNA, according to data from the IMvigor010 trial.
CTC Count Possible Biomarker for Using HER2-Directed Therapy in MBC
December 10th 2020Favorable outcomes after treatment with the HER2-directed lapatinib were indicated by early declines in circulating tumor cell counts in patients with metastatic breast cancer who initially had HER2-negative primary tumors but positive HER2 CTCs, suggesting this could serve as a clinical biomarker.
Luspatercept Demonstrates Efficacy and Tolerable Safety in Patients With MDS/MPN-RS-T
December 7th 2020Luspatercept demonstrated clinical efficacy and a tolerable safety profile in patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis who were enrolled in the MEDALIST trial.
Health-Related QoL Improvements Observed in R/R Multiple Myeloma After Cilta-Cel
December 6th 2020Patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel experienced rapid and clinically meaningful improvements in health-related quality of life and trends suggested that HRQoL benefits may be greater as responses to therapy deepen over time.